Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Other Non-current Assets
Long-term assets not reported separately.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets rises 17.2% from a year ago
Other non-current assets stood at $15.06M at the end of Q1 FY2026, up 17.2% from a year earlier and up 9.1% from the prior quarter. Over 3 fiscal years it compounded at +47.1% a year.
Context
- Other non-current assets amounted to 2.0% of total assets at the end of Q1 FY2026, down 1.8 pp from a year earlier.
- Other non-current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +17.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 13.81M USD
- Year-over-year change
- +7.4%
- 3-year CAGR
- +47.1%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.81M | +7.4% |
| FY2024 | 2024-12-31 | 12.86M | +74.6% |
| FY2023 | 2023-12-31 | 7.36M | +69.9% |
| FY2022 | 2022-12-31 | 4.33M | — |
Other Non-current Assets vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 other non-current assets of $15.06M is the highest of the 8 companies compared; the peer median is $231K.
- Its year-over-year change of +17.2% is the 2nd highest of 6, against a peer median of -40.7%.
- Other non-current assets amounts to 2.0% of total assets for ZBIO, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $15.06M | +17.2% | +47.1% | 2.0% | |
| Mar 2026 | $9.75M | +54.0% | +110.2% | 3.7% | |
| Sep 2026 | $659K | -92.5% | — | 0.1% | |
| Mar 2026 | $647K | -40.7% | — | 1.0% | |
| Mar 2026 | $231K | -92.7% | — | 0.1% | |
UPBUpstream Bio, Inc. | Mar 2026 | $194K | +0.0% | +202.6% | 0.1% |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding ZBIO) | $231K | -40.7% | +156.4% | 0.1% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.